Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Calidi Biotherapeutics, Inc. CLDI

Healthcare  —  Biotechnology
1.13 (0.07) (5.83%) as of 25 Sep
Market cap
$3.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Calidi Biotherapeutics, Inc. (CLDI) Business Profile

Updated before January 2025

Company Overview

Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other diseases by leveraging the power of oncolytic viruses and stem cell-based delivery systems. Founded in 2014, the company is headquartered in San Diego, California. Calidi’s mission is to harness the natural ability of oncolytic viruses to selectively target and destroy cancer cells while sparing healthy tissue. The company is led by a team of seasoned professionals with extensive experience in biotechnology, oncology, and pharmaceutical development. Key leadership includes CEO Allan Camaisa, who brings decades of entrepreneurial and executive experience, and Chief Scientific Officer Dr. Nikolai Tankovich, a pioneer in stem cell and oncolytic virus research.

Core Business Segments

Oncolytic Virus-Based Therapies

Calidi Biotherapeutics specializes in the development of oncolytic virus-based therapies, which use genetically engineered viruses to infect and kill cancer cells. The company’s proprietary technology platforms include:

  • NeuroNova Platform: Focused on treating glioblastoma and other brain cancers, this platform uses neural stem cells to deliver oncolytic viruses directly to tumor sites.
  • SuperNova Platform: Designed for a broader range of solid tumors, this platform combines mesenchymal stem cells with oncolytic viruses to enhance therapeutic efficacy.

Stem Cell Delivery Systems

Calidi’s innovative stem cell delivery systems are a cornerstone of its therapeutic approach. These systems protect oncolytic viruses from the immune system, allowing them to reach their target more effectively. Key products include:

  • CLD-101: A lead candidate for glioblastoma treatment, currently in clinical trials.
  • CLD-201: A pipeline product targeting metastatic cancers, leveraging the SuperNova platform.

Research and Development Services

In addition to its therapeutic products, Calidi offers R&D services to academic institutions and pharmaceutical companies. These services include preclinical testing, viral vector development, and stem cell engineering.

Business Model

Calidi Biotherapeutics operates on a hybrid business model that integrates product development, clinical trials, and strategic partnerships. The company generates revenue through:

  • Licensing Agreements: Partnering with pharmaceutical companies to co-develop and commercialize its therapies.
  • Grant Funding: Securing research grants from government agencies and non-profit organizations.
  • Collaborative Research: Offering R&D services to external partners.

Calidi’s approach emphasizes innovation, collaboration, and scalability, ensuring that its therapies can reach a global market.

Strategic Direction

Calidi Biotherapeutics is committed to advancing its pipeline of oncolytic virus-based therapies and expanding its technological platforms. Key strategic goals include:

  • Pipeline Expansion: Developing new candidates for additional cancer types and other diseases.
  • Global Partnerships: Establishing collaborations with international pharmaceutical companies to accelerate commercialization.
  • Regulatory Approvals: Securing FDA and EMA approvals for its lead candidates.
  • Sustainability Goals: Implementing eco-friendly practices in its research and manufacturing processes.

The company also aims to explore new therapeutic areas, such as autoimmune diseases and infectious diseases, leveraging its expertise in stem cell and viral vector technologies.

Competitive Landscape

Calidi Biotherapeutics operates in a highly competitive biotechnology sector. Key competitors include:

  • Amgen: A leader in oncolytic virus therapies with its Imlygic product.
  • Replimune Group: Specializing in next-generation oncolytic immunotherapies.
  • Sorrento Therapeutics: Focused on immuno-oncology and cell therapy.
  • Bluebird Bio: Known for its gene and cell therapy innovations.

Despite the competition, Calidi differentiates itself through its proprietary stem cell delivery systems and focus on glioblastoma, a market with significant unmet needs.

Risk Factors

Calidi Biotherapeutics faces several risks that could impact its operations and growth:

  • Regulatory Challenges: Delays in FDA or EMA approvals could hinder product commercialization.
  • Market Dependence: Reliance on a limited number of products increases vulnerability to market fluctuations.
  • Supply Chain Disruptions: Dependence on specialized materials and manufacturing processes poses risks.
  • Competitive Pressure: Intense competition from established players and emerging startups.
  • Clinical Trial Risks: Uncertainty in clinical trial outcomes could affect investor confidence and funding.

Recent Developments

Calidi has made significant strides in recent years, including:

  • Clinical Trials: Advancing CLD-101 into Phase II trials for glioblastoma.
  • Partnerships: Collaborating with leading academic institutions to enhance its R&D capabilities.
  • Technological Innovations: Developing next-generation stem cell delivery systems to improve therapeutic outcomes.
  • Global Expansion: Establishing a presence in Europe and Asia to access new markets.

The company has also adapted to global challenges, such as the COVID-19 pandemic, by implementing remote work policies and accelerating digital transformation.

Investment Considerations

Strengths

  • Innovative Technology: Proprietary platforms with strong IP protection.
  • Experienced Leadership: A seasoned team with a track record of success.
  • High Growth Potential: Targeting markets with significant unmet needs.
  • Strategic Partnerships: Collaborations with leading institutions and companies.

Risks

  • Early-Stage Company: Limited revenue and high R&D expenses.
  • Regulatory Uncertainty: Potential delays in product approvals.
  • Market Competition: Facing established players in the biotechnology sector.

Conclusion

Calidi Biotherapeutics is at the forefront of oncolytic virus and stem cell-based therapies, addressing critical unmet needs in oncology. With a robust pipeline, innovative technology platforms, and strategic partnerships, the company is well-positioned for growth. However, investors should consider the inherent risks associated with early-stage biotechnology companies. Overall, Calidi represents a promising opportunity for those seeking exposure to cutting-edge cancer therapies.